Estrogen receptor β (ESR2) shares a structural homology at the DNA and ligand binding domains (96% and 58%, respectively) with estrogen receptor α (ESR1), the major type of estrogen receptor in breast cancer (1,2). Similarities notwithstanding, ESR2 has functions and expression patterns distinct from ESR1 and is widely expressed in both basal and luminal epithelial cells (3–6). The exact role of ESR2 in breast cancer is not clear, with both antiproliferative and proliferative roles being described (7, 8). The mechanisms for these opposing actions of ESR2 in breast tumorigenesis have not been fully elucidated; this, in part, is due to different isoforms and binding partners.

中文翻译：

---

三阴性乳腺癌中TP53的状态和雌激素受体-β：公司的事务。

雌激素受体β（ESR2 ）在DNA和配体结合域（分别为96％和58％）与雌激素受体α（ESR1）具有相同的结构同源性，后者是乳腺癌中雌激素受体的主要类型（1,2）。尽管如此，ESR2具有不同于ESR1的功能和表达模式，并在基底和腔上皮细胞中广泛表达（3–6）。ESR2在乳腺癌中的确切作用尚不清楚，已描述了抗增殖和增生作用（7、8）。ESR2在乳腺肿瘤发生过程中这些相反作用的机制尚未完全阐明。这部分是由于不同的同工型和结合伴侣。